zur Liste
Dr. Mark Hauser
Novo Nordisk Pharma GmbH
Germany
-
Vortrag Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3 SpeakerDatum: 14.05.2021 , Zeit: 08:30 | Thema: Posterkurzvortrag
-
Vortrag Efficacy of oral semaglutide according to diabetes duration: An exploratory subgroup analysis of the PIONEER trial programme SpeakerDatum: 14.05.2021 , Zeit: 09:12 | Thema: Posterkurzvortrag